Early-stage medical device company CathVision said today it inked a “multi-million venture investment” to support the development and marketing of its electrophysiology recording system designed for treating cardiac arrhythmia.
The undisclosed investment came from Scandanavian-based VF Venture and Borean Innovation, Denmark-based CathVision said.
“CathVision works in one of the fastest growing segments in medical technology. CathVision’s team has worked patiently and consistently with their product over a number of years, and we have followed the company for several years. I think CathVision represents an attractive investment target in a market with high activity,” VF Venture managing partner Tonni Bülow-Nielsen said in a prepared statement.
“CathVision is one of the investments we have high expectations for. We have been on board since 2014 and we have now completed three capital raises in the company. We are very satisfied with the syndicate with VF Venture and look forward to the joint work towards market approval and roll-out,” Borean Innovation portfolio manager Lene Gerlach said in preapred remarks.
CathVision develops and produces a low-noise EP system designed to help guide medical professionals to the right locations for cardiac ablation. The company said it is working with leading physicians and electrophysiologists to test and market the system, and that the new investment will allow the company to conduct clinical tests and market the system.
“With the new investment and attraction of experienced investors, we are entering a new company phase towards market stage. We are working to document our advantages by conducting a series of animal and human tests in 2017-18. We are excited to bring physicians and hospitals a product that can make a difference for patients,” CathVision CEO Mads Matthiesen said in a press release.
